Eli Lilly Drug Met Trial Endpoints for Dermatitis

The ADtouch study showed successful results for lebrikizumab in treating moderate-to-severe hand and foot atopic dermatitis.

Updated on Sept. 30, 2026 in Diabetes

Isometric editorial illustration showing a pharmaceutical glass vial on a clean surface, representing clinical trial results. — Eli Lilly announced that its medication lebrikizumab met primary and secondary trial endpoints for treating moderate-to-severe hand and foot atopic dermatitis. AI Illustration. Upload story photo >

Live Poll

Do you trust that new specialty drugs for chronic skin conditions provide sufficient long-term value?

Eli Lilly announced that its medication lebrikizumab met primary and secondary endpoints in a phase 3b trial involving 221 patients. The study focused on treating moderate-to-severe hand and foot atopic dermatitis over a 16-week period.

Why it matters

This trial provides data on the efficacy of lebrikizumab for specific, hard-to-treat forms of dermatitis that affect the hands and feet. Eli Lilly has already submitted these findings to the FDA to support the continued use and expansion of the treatment.

In the ADtouch trial, 53% of patients treated with 250 mg of lebrikizumab achieved clear or almost clear skin at week 16, compared to 27% in the placebo group. Treatment-emergent adverse events occurred in 41.8% of the treatment group.

The players

Eli Lilly

Eli Lilly is a global pharmaceutical corporation that develops and markets human health medicines.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by regulating pharmaceuticals.

The details

Patients in the study received either a 250 mg dose of lebrikizumab or a placebo every 2 weeks. The trial utilized the Atopic Hand Dermatitis Clearance Satisfaction scale, finding that 77% of patients were satisfied with their hand clearance at the end of the 16-week study.

2024: Lebrikizumab received initial FDA approval for atopic dermatitis.
June 2026: The FDA approved an every-8-week maintenance dosing option.
Week 16: Final assessment of trial primary and secondary endpoints.
September 30, 2026: Eli Lilly announced the ADtouch study results.

Health Landscape

This study follows the established data requirements set by the FDA's regulatory approval process for atopic dermatitis treatments. It represents a targeted expansion of clinical research aimed at specific skin conditions that often remain underserved by standard therapies.

Patients suffering from moderate-to-severe hand and foot dermatitis may see new treatment options emerge as trial data is reviewed by global regulators. These results help clarify the efficacy of lebrikizumab for those who have not found relief through conventional topical treatments.

The takeaway

The successful trial results highlight the potential for targeted biologic treatments to address localized skin conditions. Patients should consult their dermatologists regarding current approved indications and the potential for off-label or future therapeutic access.